APA (7th ed.) Citation

Karpouzas, G. A., Szekanecz, Z., Baecklund, E., Mikuls, T. R., Bhatt, D. L., Wang, C., . . . Mortezavi, M. (2023). Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: A post hoc analysis of ORAL Surveillance. Therapeutic advances in musculoskeletal disease, 15, 1759720X231201047. https://doi.org/10.1177/1759720X231201047

Chicago Style (17th ed.) Citation

Karpouzas, George A., et al. "Rheumatoid Arthritis Disease Activity and Adverse Events in Patients Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of ORAL Surveillance." Therapeutic Advances in Musculoskeletal Disease 15 (2023): 1759720X231201047. https://doi.org/10.1177/1759720X231201047.

MLA (9th ed.) Citation

Karpouzas, George A., et al. "Rheumatoid Arthritis Disease Activity and Adverse Events in Patients Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of ORAL Surveillance." Therapeutic Advances in Musculoskeletal Disease, vol. 15, 2023, p. 1759720X231201047, https://doi.org/10.1177/1759720X231201047.